Study of osimertinib in patients with EGFR-mutated lung cancer in Spain
Part of Cancer, Lungs & breathing clinical trials.
This study is looking back at how people with EGFR-mutated non-small cell lung cancer who have taken osimertinib (Tagrisso) actually did in everyday medical care in Spain. It includes patients who took osimertinib in several different treatment scenarios.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older when you started taking osimertinib.
- You have a type of lung cancer called NSCLC with an EGFR gene mutation.
- You took osimertinib for one of these situations: as your first treatment for advanced lung cancer, after surgery for earlier stage lung cancer, combined with chemotherapy as first treatment, or after chemoradiation for locally advanced cancer.
- You are not taking osimertinib as part of another clinical trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial collects data from people with early-stage lung cancer that has a common EGFR mutation. After complete surgical removal of the tumor, participants take osimertinib for 3 years and are followed regularly to see how well the treatment works and why resistance might develop.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
This trial tests a new combination of the drug osimertinib with chemotherapy for people whose lung cancer has returned after they took osimertinib alone following surgery. It aims to see if this combined approach helps control the cancer better.
This trial tests whether adding a new drug (SYS6010) to the standard targeted therapy osimertinib before surgery can help shrink EGFR-positive lung tumors more than osimertinib alone. It is for people with early-stage (II to IIIB) non-small cell lung cancer that can be removed surgically.
This trial tests whether removing the main lung tumor with surgery and then taking the targeted drug osimertinib helps people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if this approach can improve outcomes compared to just taking the drug alone.
This trial tests a new combination of two drugs (BL-B01D1 and osimertinib) versus osimertinib alone as the first treatment for people with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination works better at stopping the cancer from growing.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.